UCSF Helen Diller Comprehensive Cancer Center

University of California San Francisco

San Francisco, CA

Sorting 3 by

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1
  • Myeloma Service

Accepting patients

MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Learn more
  • Phase 1
  • Myeloma Service
  • 23-222

Accepting patients

JNJ-79635322

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Learn more
  • BCMA
  • GPRC5D
  • Tri-specific Antibody
  • Phase 1
  • Myeloma Service